EMD Serono takes on exclusive promotion of Rebif in USA

EMD Serono, the North American biopharma business of Germany’s Merck KGaA (MRK: DE), has taken on the sole rights to Rebif (interferon beta-1a) in the USA as of January 1.

Rebif, the number one prescribed interferon for relapsing multiple sclerosis (MS) in patients new to therapy in the USA, is now the exclusive interferon beta-1a on CVS Caremark National Formulary and will also continue to be covered on most major national formulary plans.

"We have also evolved our award-winning MS LifeLines patient support service with the goal of providing a broad range of comprehensive assistance to people living with relapsing MS," said Drew Young, senior vice president, neurology and immunology, EMD Serono. "Since reimbursement can often be complicated for patients to navigate, we are working to ensure that all eligible patients are aware of our comprehensive suite of patient support programs, including our reimbursement support," he added.